Expert commentary from Haberman Associates biotechnology and pharmaceutical consulting. Moved our blog from Blogspot to this location on our own site in May 2010. The main them of the blog is R&D strategy—especially productive R&D strategies--in the biotechnology and pharmaceutical industry and other life science companies. The blog contains commentary on recent news and/or recent published scientific reports or business articles, and a few announcements and commentaries on Haberman Associates publications and events.
Recent blog post
FDA proposes accelerated approval of early-stage Alzheimer’s drugs based on cognitive improvement alone
Pittsburgh compound B staining in AD. Source: National Institute on Aging/NIH. In our February 28, 2013 article on the Biopharmconsortium Blog, we discussed the FDA’s February 7, 2013 Draft Guidance for Industry entitled “Alzheimer’s Disease: Developing...6 weeks ago
User reviewsPersonal attacks are NOT allowed
Please read our comment policy